Article Text

other Versions

PDF
Research paper
FRONTIER Executive Screen: a brief executive battery to differentiate frontotemporal dementia and Alzheimer's disease
  1. F V C Leslie1,2,3,
  2. D Foxe1,
  3. N Daveson1,
  4. E Flannagan1,
  5. J R Hodges1,2,3,
  6. O Piguet1,2,3
  1. 1Neuroscience Research Australia, Sydney, New South Wales, Australia
  2. 2School of Medical Science, University of New South Wales, Sydney, New South Wales, Australia
  3. 3ARC Centre of Excellence in Cognition and its Disorders, University of New South Wales, Sydney, New South Wales, Australia
  1. Correspondence to Dr Olivier Piguet, Neuroscience Research Australia, Barker Street, Randwick NSW 2031, Australia; o.piguet{at}neura.edu.au

Abstract

Background and objective Executive dysfunctions are a key clinical feature of behavioural-variant frontotemporal dementia (bvFTD). Such deficits are also found in Alzheimer's disease (AD), making the differentiation between these two diseases difficult at times, particularly in the absence of extensive cognitive assessments. To address this issue, we developed the FRONTIER Executive Screen (FES), which combines three abbreviated measures of verbal fluency, inhibitory control and working memory.

Methods We administered the FES to 28 patients with dementia (14 bvFTD, 14 AD) matched for disease severity and 33 age-matched and education-matched healthy controls. We also administered traditional tests of executive function to establish the concurrent validity of the FES.

Results Both patient groups obtained lower FES scores (total and subscores) compared to controls. Correct classification into patient or control groups was reached in over 90% of study participants based on the FES total score. Only two patients with bvFTD obtained FES scores within 2 SDs of the control group. Receiver operating characteristic analyses on the patient groups showed that a cut-off FES total score of 7/15 achieved 71% sensitivity and 73% specificity for a diagnosis of bvFTD. In addition, the FES showed high correlations with traditional measures of executive function.

Conclusions The FES is a brief (5–10 min) bedside screening measure which is simple to administer and score, and demonstrates good discriminative validity to differentiate bvFTD from AD. It is a useful addendum to general cognitive screening measures and can help with the differential diagnosis of dementia.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.